Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients

Radiother Oncol. 2023 Jul:184:109699. doi: 10.1016/j.radonc.2023.109699. Epub 2023 May 9.

Abstract

Purpose: To compare the acute toxicity of two different induction chemotherapy (IndCT) regimen followed by the same IMRT in patients with advanced nasopharyngeal carcinoma (NPC).

Materials and methods: From July 2015 to December 2016, 110 NPC patients with stage III-IV diseases were prospectively randomized to receive either a conventional triweekly cisplatin + 5-fluorouracil (PF) for 3 cycles or weekly P-F for 10 doses, followed by the same IMRT to both arms. The primary endpoints of this study were grade 3/4 and any grade acute toxicities during IndCT period. The secondary endpoints included tumor response and various survivals.

Results: Baseline patient characteristics were comparable in both groups. Patients who received weekly P-F experienced significant reduction of grade 3/4 acute toxicities, including neutropenia (12.7% vs. 40.0%, P = 0.0012), anorexia (0% vs. 14.6%, P = 0.0059), mucositis (0% vs. 14.6%, P = 0.0059), and hyponatremia (0% vs. 16.4%, P = 0.0027), compared with the triweekly PF group, resulting in fewer IndCT interruptions (1.8% vs. 16.4%, P = 0.0203), emergency room visits (0% vs. 12.7%, P = 0.0128), and additional hospitalizations (0% vs. 9.1%, P = 0.0568). The acute toxicities during IMRT period were similar. Weekly P-F arm had higher complete response rates (83.6% vs. 61.8%, P = 0.0152) and lower relapse rates (16.4% vs. 33.3%, P = 0.0402) after a median follow-up of 67 months. Kaplan-Meier survival analyses revealed a better trend of locoregional failure-free (P = 0.0892), distant metastasis failure-free (P = 0.0775), and progression-free (P = 0.0709) survivals, favoring the weekly P-F arm.

Conclusion: IndCT of weekly schedule does reduce acute toxicities without compromised tumor response and survivals.

Keywords: Acute toxicity; Induction chemotherapy; Nasopharyngeal carcinoma; Radiotherapy.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Chemoradiotherapy / adverse effects
  • Cisplatin* / adverse effects
  • Disease-Free Survival
  • Fluorouracil / adverse effects
  • Humans
  • Induction Chemotherapy / adverse effects
  • Nasopharyngeal Carcinoma / drug therapy
  • Nasopharyngeal Neoplasms* / pathology
  • Neoplasm Recurrence, Local / drug therapy
  • Treatment Outcome

Substances

  • Cisplatin
  • Fluorouracil